Skip to Content

Posts tagged with "Alzheimer’s Disease"

  • Alzheimer's Disease

    Does Glucophage Make Alzheimer’s Worse?

    Metformin, now there’s a drug story for you. It’s a startlingly small molecule, the sort of thing that chemists look and and say “That’s a real drug?” It kicked around in the literature and the labs in the 1960s, was marketed in Europe in the 1980s but was shopped around in the US for quite… Read More
  • Alzheimer's Disease

    Short Items: India, Sanjay Gupta, Satori Pharmaceuticals

    I have a few short links for everyone today. One series of posts that you might not have seen from Xconomy is a tour of the technological hot spots of India by Boston University’s Vinit Nijhawan. It’s interesting stuff for people like me who haven’t been to the country, and he isn’t shy about pointing… Read More
  • Alzheimer's Disease

    Where Are the Drugs?

    A recent correspondence on the topic of “Why aren’t there more drugs for the big CNS disorders” got me thinking about the topic. My take, having worked in the field, is that there is still so much unmet need in that area because we just don’t understand what’s going on. It’s hard to come up… Read More
  • Alzheimer's Disease

    Rember for Alzheimer’s: Methylene Blue’s Comeback

    Today we take up the extremely interesting story of Rember, hailed in this week’s press as a potential wonder drug for Alzheimer’s. There are a lot of unusual features to this one. To take the most obvious first, the Phase II data seem to have been impressive. It’s hard to show decent efficacy in an… Read More
  • Alzheimer's Disease

    Bapineuzumab: Good For Anything or Not?

    Note: I’m still working my way through the information on the much-hyped TauRx drug, Rember – a post on that is coming. Here’s more from the same Alzheimer’s meeting, though: Elan and Wyeth unveiled the data on their widely anticipated Alzheimer’s drug bapineuzumab yesterday. This is another antibody from Elan’s shop, pa… Read More
  • Alzheimer's Disease

    Patents Stopping an Alzheimer’s Wonder Drug?

    A longtime reader sent along a very interesting example that’s being used in a new book. The Gridlock Economy by Columbia economist Michael Heller is getting some good press, including this interview over at the Wall Street Journal>’s Law Blog. Heller’s thesis is: “When too many owners control a single resource, cooperation breaks down, wea… Read More
  • Alzheimer's Disease

    Another Alzheimer’s Compound Goes Down

    I was mentioning the gamma secretase enzyme around here just the other day as a longstanding target for Alzheimer’s therapy. I remember the periodduring the 1990s when the enzyme hadn’t been identified yet, and frankly, it was a lot easier to get excited about it then. That’s because when it was finally worked out, the… Read More
  • Alzheimer's Disease

    Protecting Amyloid’s Parent?

    Let’s start from first principles: most drugs mess something up. More elegantly, most drugs inhibit some enzyme’s activity or block some receptor’s binding site. Proteins are generally pretty well optimized at what they do, so it’s a lot easier to block their activities than it is to speed them up. (There are rare exceptions). And… Read More
  • Alzheimer's Disease

    Elan Tries Again

    The long-running saga of Elan’s attempt to come up with a vaccine for Alzheimer’s disease continues. There have been bold attempts, setbacks, rethinks, more setbacks, and now they’re starting up again. Dosing of the latest version of their vaccine against the beta-amyloid protein, known as ACC-001, was suddenly halted in April whe… Read More
  • Alzheimer's Disease

    In Which I Hate A Wonder Drug

    Schering-Plough has had its share of troubles over the years, but the company has also seen itself saved by some pretty unlikely compounds. Vytorin (ezetimibe) is the example I’ve spoken about here, and if the drug doesn’t seem like a savior at the moment, well, you have to keep in mind that it was the… Read More
...111213...